title: The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
abstract: Tumor flare is reported in up to 40% of patients treated with gonadotrophin-releasing hormone analogues for prostate cancer. In order to investigate the optimal way to eliminate tumor flare, we have treated patients with one of three different antiandrogen regimens used in combination with gonadotrophin-releasing hormone (GnRH) agonist. The early results of this study are presented here. Thirty patients with advanced symptomatic disease were randomized to receive either cyproterone acetate 50 or 100 mg three times daily or flutamide 250 mg three times daily given for 1 week before and during the first month of GnRH agonist treatment. The endocrine profiles of these patients were compared with those of historic controls treated with depot agonist alone. Three patients treated with low-dose cyproterone acetate and one with flutamide developed a transient exacerbation of their disease. No patients treated with the higher-dose cyproterone acetate regimen developed tumor flare. No patients treated with cyproterone acetate had an increase in serum testosterone above baseline following depot GnRH agonist implantation. All patients treated with flutamide had increases in serum testosterone, but this did not significantly increase further with implantation. This study suggests that all patients receiving GnRH agonist treatment should be pretreated with cyproterone acetate 100 mg three times daily for 1 week before implantation and for the first treatment month.
authors.affiliation: Department of Clinical Oncology, Hammersmith Hospital, London, England.
authors.forename: J
authors.initials: J
authors.lastname: Waxman
authors.forename: G
authors.initials: G
authors.lastname: Williams
authors.forename: J
authors.initials: J
authors.lastname: Sandow
authors.forename: G
authors.initials: G
authors.lastname: Hewitt
authors.forename: P
authors.initials: P
authors.lastname: Abel
authors.forename: N
authors.initials: N
authors.lastname: Farah
authors.forename: J
authors.initials: J
authors.lastname: Fleming
authors.forename: J
authors.initials: J
authors.lastname: Cox
authors.forename: E P
authors.initials: EP
authors.lastname: O'Donoghue
authors.forename: K
authors.initials: K
authors.lastname: Sikora
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002064:Buserelin / Q000008:administration & dosage; D003534:Cyproterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017373:Cyproterone Acetate; D003692:Delayed-Action Preparations; D005485:Flutamide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D010744:Phosphoric Monoester Hydrolases / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D011897:Random Allocation; D013739:Testosterone / Q000097:blood
chemical_list: D003692:Delayed-Action Preparations; D013739:Testosterone; D017373:Cyproterone Acetate; D005485:Flutamide; D003534:Cyproterone; D010744:Phosphoric Monoester Hydrolases; D002064:Buserelin